StandardStandard

Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. / Hope, Vivian D; McVeigh, Jim; Marongiu, Andrea et al.
Yn: BMJ Open, Cyfrol 3, Rhif 9, 12.09.2013, t. e003207.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Hope, VD, McVeigh, J, Marongiu, A, Evans-Brown, M, Smith, J, Kimergård, A, Croxford, S, Beynon, CM, Parry, JV, Bellis, MA & Ncube, F 2013, 'Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study', BMJ Open, cyfrol. 3, rhif 9, tt. e003207. https://doi.org/10.1136/bmjopen-2013-003207

APA

Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergård, A., Croxford, S., Beynon, C. M., Parry, J. V., Bellis, M. A., & Ncube, F. (2013). Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open, 3(9), e003207. https://doi.org/10.1136/bmjopen-2013-003207

CBE

Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Croxford S, Beynon CM, Parry JV, Bellis MA, et al. 2013. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 3(9):e003207. https://doi.org/10.1136/bmjopen-2013-003207

MLA

VancouverVancouver

Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013 Medi 12;3(9):e003207. doi: 10.1136/bmjopen-2013-003207

Author

Hope, Vivian D ; McVeigh, Jim ; Marongiu, Andrea et al. / Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs : a cross-sectional study. Yn: BMJ Open. 2013 ; Cyfrol 3, Rhif 9. tt. e003207.

RIS

TY - JOUR

T1 - Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs

T2 - a cross-sectional study

AU - Hope, Vivian D

AU - McVeigh, Jim

AU - Marongiu, Andrea

AU - Evans-Brown, Michael

AU - Smith, Josie

AU - Kimergård, Andreas

AU - Croxford, Sara

AU - Beynon, Caryl M

AU - Parry, John V

AU - Bellis, Mark A

AU - Ncube, Fortune

PY - 2013/9/12

Y1 - 2013/9/12

N2 - OBJECTIVE: To describe drug use, sexual risks and the prevalence of blood-borne viral infections among men who inject image and performance enhancing drugs (IPEDs).DESIGN: A voluntary unlinked-anonymous cross-sectional biobehavioural survey.SETTING: 19 needle and syringe programmes across England and Wales.PARTICIPANTS: 395 men who had injected IPEDs.RESULTS: Of the participants (median age 28 years), 36% had used IPEDs for <5 years. Anabolic steroids (86%), growth hormone (32%) and human chorionic gonadotropin (16%) were most frequently injected, with 88% injecting intramuscularly and 39% subcutaneously. Two-thirds also used IPEDs orally. Recent psychoactive drug use was common (46% cocaine, 12% amphetamine), 5% had ever injected a psychoactive drug and 9% had shared injecting equipment. 'Viagra/Cialis' was used by 7%, with 89% reporting anal/vaginal sex in the preceding year (20% had 5+ female-partners, 3% male-partners) and 13% always using condoms. Overall, 1.5% had HIV, 9% had antibodies to the hepatitis B core antigen (anti-HBc) and 5% to hepatitis C (anti-HCV). In multivariate analysis, having HIV was associated with: seeking advice from a sexual health clinic; having had an injection site abscess/wound; and having male partners. After excluding those reporting male partners or injecting psychoactive drugs, 0.8% had HIV, 8% anti-HBc and 5% anti-HCV. Only 23% reported uptake of the hepatitis B vaccine, and diagnostic testing uptake was poor (31% for HIV, 22% for hepatitis C).CONCLUSIONS: Previous prevalence studies had not found HIV among IPED injectors. HIV prevalence in this, the largest study of blood-borne viruses among IPED injectors, was similar to that among injectors of psychoactive drugs. Findings indicate a need for targeted interventions.

AB - OBJECTIVE: To describe drug use, sexual risks and the prevalence of blood-borne viral infections among men who inject image and performance enhancing drugs (IPEDs).DESIGN: A voluntary unlinked-anonymous cross-sectional biobehavioural survey.SETTING: 19 needle and syringe programmes across England and Wales.PARTICIPANTS: 395 men who had injected IPEDs.RESULTS: Of the participants (median age 28 years), 36% had used IPEDs for <5 years. Anabolic steroids (86%), growth hormone (32%) and human chorionic gonadotropin (16%) were most frequently injected, with 88% injecting intramuscularly and 39% subcutaneously. Two-thirds also used IPEDs orally. Recent psychoactive drug use was common (46% cocaine, 12% amphetamine), 5% had ever injected a psychoactive drug and 9% had shared injecting equipment. 'Viagra/Cialis' was used by 7%, with 89% reporting anal/vaginal sex in the preceding year (20% had 5+ female-partners, 3% male-partners) and 13% always using condoms. Overall, 1.5% had HIV, 9% had antibodies to the hepatitis B core antigen (anti-HBc) and 5% to hepatitis C (anti-HCV). In multivariate analysis, having HIV was associated with: seeking advice from a sexual health clinic; having had an injection site abscess/wound; and having male partners. After excluding those reporting male partners or injecting psychoactive drugs, 0.8% had HIV, 8% anti-HBc and 5% anti-HCV. Only 23% reported uptake of the hepatitis B vaccine, and diagnostic testing uptake was poor (31% for HIV, 22% for hepatitis C).CONCLUSIONS: Previous prevalence studies had not found HIV among IPED injectors. HIV prevalence in this, the largest study of blood-borne viruses among IPED injectors, was similar to that among injectors of psychoactive drugs. Findings indicate a need for targeted interventions.

KW - Journal Article

U2 - 10.1136/bmjopen-2013-003207

DO - 10.1136/bmjopen-2013-003207

M3 - Article

C2 - 24030866

VL - 3

SP - e003207

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 9

ER -